# Study of ZIO-101 in Multiple Myeloma

> **NCT00303199** · PHASE1,PHASE2 · COMPLETED · sponsor: **Alaunos Therapeutics** · enrollment: 35 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** ZIO-101 (Darinaparsin)

## Key facts

- **NCT ID:** NCT00303199
- **Lead sponsor:** Alaunos Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-01
- **Primary completion:** 2007-08
- **Final completion:** 2007-08
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2012-07-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00303199

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00303199, "Study of ZIO-101 in Multiple Myeloma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00303199. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*